文献速递脊柱关节炎

脊柱关节炎是否需要新的试验设计?

Do we need new trial designs in spondyloarthritis?
PubMed 文献 · Semin Arthritis Rheum · 2019-01-01

本文讨论在axSpA疾病谱扩展背景下,药物试验设计需优化的问题。文章提出可考虑附加治疗标准(MRI和CRP阳性)、更好的疗效测量(ASDAS)及试验同质性,以改进药物测试与审批流程。

要点

  • axSpA新分类标准扩展了疾病谱,使nr-axSpA患者可纳入药物试验。
  • 优化试验设计可考虑附加MRI和CRP阳性标准以提高同质性。
  • ASDAS可作为更好的疗效测量工具用于试验设计。

核心结论

  • 在axSpA疾病谱扩展的环境下,药物试验设计需要调整以优化药物测试与审批流程。

研究设计与样本

  • 本文为综述/观点性文章,讨论AS药物试验成功历史及axSpA新分类标准对试验设计的影响。

主要发现

  • 过去二十年AS药物试验非常成功,多种有效新药获批用于AS治疗。
  • 2009年axSpA新分类标准不仅涵盖AS,也涵盖推测更早期的nr-axSpA患者。
  • 这些分类标准已被用作nr-axSpA药物试验的入组标准。

关键数值与推荐

  • 附加治疗标准包括MRI阳性和CRP阳性。
  • 更好的疗效测量为ASDAS。
  • 试验同质性是需要关注的方面。

临床怎么用

  • 在axSpA药物试验设计中可考虑附加MRI和CRP阳性标准、采用ASDAS测量疗效并关注试验同质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last two decades drug trials in ankylosing spondylitis (AS) have been extremely successful and many effective new drugs have been approved for the treatment of patients with AS. In 2009, new classification criteria for axial spondyloarthritis (axSpA) have been released that capture not only AS, but also patients with presumably earlier non-radiographic axSpA. These criteria have served as inclusion criteria for patients to be enrolled in drug trials for the indication of nr-axSpA. The theme to be discussed in this article pertains to changes in the design of clinical trials required to optimize the process of drug-testing and -approval in a changed environment. Additional treatment criteria (MRI-and CRP-positivity), better response measurement (ASDAS) and trial homogeneity will be addressed against the background of the expansion of the disease spectrum of axSpA which has been the consequence of the new classification criteria for axSpA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Landewé RBM. Do we need new trial designs in spondyloarthritis? Semin Arthritis Rheum. 2019. PMID: 31779854. doi:10.1016/j.semarthrit.2019.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。